Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | EP300 | Q09472 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15155737 | 0.89 | HTT (0.61) | HTTSMN1; SMN2PDE4BKMT2AEP300 | |
| SCHEMBL29417627 | 0.83 | HTT (0.48) | HTTSMN1; SMN2PDE4BKMT2ATSHR | |
| SCHEMBL19582321 | 0.83 | HTT (0.48) | HTTSMN1; SMN2PDE4BKMT2ATSHR | |
| SCHEMBL30206676 | 0.83 | HTT (0.48) | HTTSMN1; SMN2PDE4BKMT2ATSHR | |
| SCHEMBL16884088 | 0.83 | HTT (0.76) | HTTSMN1; SMN2PDE4BKMT2ATSHR | |
| SCHEMBL30206675 | 0.82 | HTT (0.47) | HTTSMN1; SMN2PDE4BKMT2ATSHR | |
| SCHEMBL30206828 | 0.82 | HTT (0.47) | HTTSMN1; SMN2KMT2ATSHRMEN1 | |
| SCHEMBL7413309 | 0.82 | GAA (0.55) | HTTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL22839725 | 0.81 | HTT (0.46) | HTTSMN1; SMN2PDE4BKMT2ATSHR | |
| SCHEMBL519845 | 0.79 | HTT (0.70) | HTTSMN1; SMN2PDE4BKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238656-B2 | Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders | CEPHALON, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2809671-B1 | IMIDAZO [4, 5 - B]PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CEPHALON INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | CEPHALON, INC. | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | JAK1, ALK, JAK2 | HTT 4331/4885SMN1; SMN2 4305/4885PDE4B 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.